Human Viruses

WHO Admits to Releasing Pandemic Virus into Population via Mock-Up Vaccines
Dr. Mercola
Mercola.com
September 5, 2009

The document on the WHO website linked below states that it is common procedure to release pandemic viruses into the population in order to get a jump ahead of the real pandemic, so as to fast track the vaccine for when it is needed.

In Europe, some manufacturers have conducted advance studies using a so-called mock-up vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus.

According to the website, Such advance studies can greatly expedite regulatory approval.

Sources: World Health Organization

Dr. Mercolas Comments:

On June 11 the World Health Organization (WHO) raised its swine flu pandemic alert from a 5 to a 6. Phase 6 is the highest level alert, and reflects the speed with which a virus is spreading — not its severity.

This classification also allows for a vaccine to qualify for a fast-track procedure for licensing and approval, and this process is now ongoing for the swine flu vaccine.

What you may not know, however, is that WHO, together with health officials, regulatory authorities and vaccine manufacturers, have been working since 2007 long before this new threat of swine flu emerged to explore a broad range of issues surrounding the regulatory approval of pandemic vaccines.

According to the WHO website:

Ways were sought to shorten the time between the emergence of a pandemic virus and the availability of safe and effective vaccines.

One such method used in Europe is to conduct advance studies using a mock-up vaccine that contains an active ingredient for an influenza virus that has not circulated recently in human populations.

When testing these mock-up vaccines, it is very possible to release the novel influenza virus into the population, as its purpose is to mimic the novelty of a pandemic virus and greatly expedite regulatory approval.

Government officials have other tricks up their sleeves to ensure these new, barely tested vaccines easily make it to market as well, such as:

Labeling the vaccine a strain change rather than an entirely new vaccine. This method states the new vaccine has built on technology used to produce vaccines for seasonal influenza, and the change for the pandemic vaccine is similar to a strain change used to produce a new seasonal vaccine each flu season.
In the United States, vaccine manufacturers are required to submit fewer data if they already have a licensed flu vaccine and will use the same manufacturing process for the pandemic vaccine.

Using a rolling review procedure. This allows manufacturers to submit sets of data for regulatory review as they become available. In other words, theyre free to distribute the vaccine and then submit the safety data later on.
http://www.infowars.com/who-admits-to-releasing-pandemic-virus-into-population-via-mock-up-vaccines/
http://prisonplanet.tv/
http://www.ae911truth.org/